$CRSP
CRISPR Therapeutics AG

2021 Q2 Form 10-Q Financial Statement

#000156459021039178 Filed on July 29, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $900.7M $44.00K
YoY Change 2046947.73% -86.16%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $29.81M $21.40M
YoY Change 39.28% 35.44%
% of Gross Profit
Research & Development $82.33M $59.38M
YoY Change 38.65% 50.2%
% of Gross Profit
Depreciation & Amortization $3.600M $2.200M
YoY Change 63.64% 120.0%
% of Gross Profit
Operating Expenses $138.1M $80.73M
YoY Change 71.04% 45.99%
Operating Profit $762.6M -$80.69M
YoY Change -1045.13% 46.75%
Interest Expense $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $750.0K $1.412M
YoY Change -46.88% 3.14%
Pretax Income $763.4M -$79.28M
YoY Change -1062.91% 47.87%
Income Tax $4.100M $400.0K
% Of Pretax Income 0.54%
Net Earnings $759.2M -$79.66M
YoY Change -1053.13% 48.34%
Net Earnings / Revenue 84.29% -181036.36%
Basic Earnings Per Share $10.01 -$1.30
Diluted Earnings Per Share $9.44 -$1.30
COMMON SHARES
Basic Shares Outstanding 75.83M 61.42M
Diluted Shares Outstanding 80.45M 61.42M

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.627B $945.1M
YoY Change 177.99% 120.87%
Cash & Equivalents $1.647B $945.1M
Short-Term Investments $980.6M
Other Short-Term Assets $31.35M $20.50M
YoY Change 52.91% 99.03%
Inventory
Prepaid Expenses
Receivables $150.0K $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $2.621B $965.6M
YoY Change 171.43% 120.22%
LONG-TERM ASSETS
Property, Plant & Equipment $75.41M $34.44M
YoY Change 118.95% 70.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $23.63M $7.000M
YoY Change 237.54% 946.34%
Total Long-Term Assets $278.6M $80.90M
YoY Change 244.35% 45.05%
TOTAL ASSETS
Total Short-Term Assets $2.621B $965.6M
Total Long-Term Assets $278.6M $80.90M
Total Assets $2.900B $1.047B
YoY Change 177.07% 111.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.15M $13.20M
YoY Change -23.14% 84.8%
Accrued Expenses $67.10M $36.69M
YoY Change 82.91% 96.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $99.92M $74.50M
YoY Change 34.12% 137.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $195.8M $61.40M
YoY Change 218.89% 27809.09%
Total Long-Term Liabilities $195.8M $61.40M
YoY Change 218.89% 27809.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $99.92M $74.50M
Total Long-Term Liabilities $195.8M $61.40M
Total Liabilities $295.7M $135.9M
YoY Change 117.6% 7.38%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.604B $910.7M
YoY Change
Total Liabilities & Shareholders Equity $2.900B $1.047B
YoY Change 177.07% 111.74%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income $759.2M -$79.66M
YoY Change -1053.13% 48.34%
Depreciation, Depletion And Amortization $3.600M $2.200M
YoY Change 63.64% 120.0%
Cash From Operating Activities $807.0M -$29.27M
YoY Change -2857.09% -19.54%
INVESTING ACTIVITIES
Capital Expenditures -$28.45M -$3.610M
YoY Change 688.17% 66.36%
Acquisitions
YoY Change
Other Investing Activities -$265.2M
YoY Change
Cash From Investing Activities -$293.6M -$3.610M
YoY Change 8033.91% 66.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.444M 89.51M
YoY Change -90.57% 201.89%
NET CHANGE
Cash From Operating Activities 807.0M -29.27M
Cash From Investing Activities -293.6M -3.610M
Cash From Financing Activities 8.444M 89.51M
Net Change In Cash 521.8M 56.63M
YoY Change 821.44% -736.29%
FREE CASH FLOW
Cash From Operating Activities $807.0M -$29.27M
Capital Expenditures -$28.45M -$3.610M
Free Cash Flow $835.5M -$25.66M
YoY Change -3355.85% -24.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
900701000
CY2021Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
750000
CY2020Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1412000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
2705000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
5644000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-148631000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4718000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
756000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
10000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-28000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-173000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-556000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
759057000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-79659000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
645516000
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
10.01
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
8.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.44
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75826594
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61420746
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75418160
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61134214
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
9.44
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.30
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
8.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.44
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80449956
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61420746
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80458855
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61134214
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
939425000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14151000
CY2020Q1 us-gaap Stock Issued During Period Value Treasury Stock Reissued
StockIssuedDuringPeriodValueTreasuryStockReissued
889000
CY2021Q1 crsp Stock Purchased During Period Value Employee Stock Purchase Plan
StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan
751000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22092000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-378000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-113163000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
1805498000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10909000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28331000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-168000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
759225000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
2603795000
us-gaap Profit Loss
ProfitLoss
646062000
us-gaap Profit Loss
ProfitLoss
-149387000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6368000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4283000
us-gaap Share Based Compensation
ShareBasedCompensation
50423000
us-gaap Share Based Compensation
ShareBasedCompensation
29848000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-4417000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-889000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-66000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-271000
crsp Increase Decrease In Operating Lease Assets And Liabilities
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
1259000
crsp Increase Decrease In Operating Lease Assets And Liabilities
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
-111000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-5870000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-3652000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
706339000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-81454000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
35473000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6596000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
715982000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
289921000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-461534000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6596000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
213267000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
83021000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
21167000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
7616000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
479249000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2559000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1185468000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
948812000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1664717000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
7533000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2585000
crsp Equity Issuance Costs In Accounts Payable And Accrued Expenses
EquityIssuanceCostsInAccountsPayableAndAccruedExpenses
402000
crsp Equity Issuance Costs In Accounts Payable And Accrued Expenses
EquityIssuanceCostsInAccountsPayableAndAccruedExpenses
1009000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1646646000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
945068000
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
18071000
CY2020Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
6303000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1664717000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
951371000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q2 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Losses Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedLossesBeforeTax
772000
CY2021Q2 crsp Cash Equivalents And Available For Sale Debt Securities Fair Value
CashEquivalentsAndAvailableForSaleDebtSecuritiesFairValue
1608826000
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
773560000
CY2020Q4 crsp Cash Equivalents Gross Unrealized Gains Before Tax
CashEquivalentsGrossUnrealizedGainsBeforeTax
1000
CY2020Q4 crsp Cash Equivalents Gross Unrealized Losses Before Tax
CashEquivalentsGrossUnrealizedLossesBeforeTax
24000
CY2020Q4 crsp Cash Equivalents Fair Value
CashEquivalentsFairValue
773537000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
521820000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
51000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
158000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
521713000
CY2020Q4 crsp Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
1295380000
CY2020Q4 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Gains Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedGainsBeforeTax
52000
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
770000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
942800000
CY2021Q2 crsp Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
1609512000
CY2021Q2 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Gains Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedGainsBeforeTax
86000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. <span style="color:#212529;">On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, revenue recognition, equity-based compensation expense and reported amounts of expenses during the period. Significant estimates in these consolidated financial statements have been made in connection with revenue recognition and equity-based compensation expense. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</span><span style="color:#000000;"> Changes in estimates are reflected in reported results in the period in which they become known.</span></p>
CY2021Q2 us-gaap Marketable Securities
MarketableSecurities
980600000
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
395100000
CY2021Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
666028000
CY2021Q2 crsp Cash Equivalents Gross Unrealized Losses Before Tax
CashEquivalentsGrossUnrealizedLossesBeforeTax
2000
CY2021Q2 crsp Cash Equivalents Fair Value
CashEquivalentsFairValue
666026000
CY2021Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
943484000
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
86000
CY2020Q4 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Losses Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedLossesBeforeTax
182000
CY2020Q4 crsp Cash Equivalents And Available For Sale Debt Securities Fair Value
CashEquivalentsAndAvailableForSaleDebtSecuritiesFairValue
1295250000
CY2021Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
622600000
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
280300000
CY2021Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
CY2021Q2 crsp Credit Related Impairment Charges For Marketable Securities
CreditRelatedImpairmentChargesForMarketableSecurities
0
crsp Credit Related Impairment Charges For Marketable Securities
CreditRelatedImpairmentChargesForMarketableSecurities
0
CY2021Q2 crsp Debt Securities Available For Sale Securities Remaining Maturity Greater Than Three Year
DebtSecuritiesAvailableForSaleSecuritiesRemainingMaturityGreaterThanThreeYear
0
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
102930000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
63335000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
27516000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
21175000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
75414000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42160000
CY2021Q2 us-gaap Depreciation
Depreciation
3600000
us-gaap Depreciation
Depreciation
6300000
CY2020Q2 us-gaap Depreciation
Depreciation
2200000
us-gaap Depreciation
Depreciation
4300000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
15325000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
22402000
CY2021Q2 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
34023000
CY2020Q4 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
21684000
CY2021Q2 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
150000
CY2020Q4 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
1401000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3085000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1670000
CY2021Q2 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
6941000
CY2020Q4 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
3625000
CY2021Q2 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
7127000
CY2020Q4 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
2835000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
450000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
165000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
67101000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
53782000
crsp Joint Venture Agreement Date
JointVentureAgreementDate
2015-12-19
CY2021Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
6784000
CY2021Q2 crsp Prepaid Expenses And Other Current Assets Fair Value Disclosure
PrepaidExpensesAndOtherCurrentAssetsFairValueDisclosure
2565000
CY2021Q2 us-gaap Property Plant And Equipment Fair Value Disclosure
PropertyPlantAndEquipmentFairValueDisclosure
9340000
CY2021Q2 crsp Operating Lease Assets Fair Value Disclosure
OperatingLeaseAssetsFairValueDisclosure
11003000
CY2021Q2 crsp Restricted Cash Fair Value Disclosure
RestrictedCashFairValueDisclosure
1226000
CY2021Q2 crsp Accrued Expenses And Other Current Liabilities Fair Value Disclosure
AccruedExpensesAndOtherCurrentLiabilitiesFairValueDisclosure
3915000
CY2021Q2 crsp Operating Lease Liabilities Fair Value Disclosure
OperatingLeaseLiabilitiesFairValueDisclosure
11003000
CY2021Q2 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
16000000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
145364335
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2021Q2 crsp Common Stock Registered Share Capital
CommonStockRegisteredShareCapital
80321227
CY2020Q4 crsp Common Stock Registered Share Capital
CommonStockRegisteredShareCapital
75133951
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
145364335
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115172786
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28331000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15697000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
50423000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29848000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8101980
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
42.44
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1074458
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
135.81
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
686548
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
32.97
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
141351
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
54.14
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8348539
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
55.03
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4141831
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
34.08
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8348539
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
55.03
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
183600000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
759225000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-79656000
us-gaap Net Income Loss
NetIncomeLoss
646062000
us-gaap Net Income Loss
NetIncomeLoss
-149387000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75826594
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61420746
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75418160
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61134214
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80449956
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61420746
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80458855
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61134214
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.30
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
10.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
8.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.44
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
9.44
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.30
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
8.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.44
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2332647
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9134136
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1694486
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9134136
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4100000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4700000
CY2021Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.005
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.007
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
400000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
800000
CY2020Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.005
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.005

Files In Submission

Name View Source Status
0001564590-21-039178-index-headers.html Edgar Link pending
0001564590-21-039178-index.html Edgar Link pending
0001564590-21-039178.txt Edgar Link pending
0001564590-21-039178-xbrl.zip Edgar Link pending
crsp-10q_20210630.htm Edgar Link pending
crsp-10q_20210630_htm.xml Edgar Link completed
crsp-20210630.xsd Edgar Link pending
crsp-20210630_cal.xml Edgar Link unprocessable
crsp-20210630_def.xml Edgar Link unprocessable
crsp-20210630_lab.xml Edgar Link unprocessable
crsp-20210630_pre.xml Edgar Link unprocessable
crsp-ex101_103.htm Edgar Link pending
crsp-ex102_184.htm Edgar Link pending
crsp-ex311_9.htm Edgar Link pending
crsp-ex312_11.htm Edgar Link pending
crsp-ex321_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gaohwwcqhi4e000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending